Pemetrexed exposure predicts toxicity in advanced non–small-cell lung cancer: A prospective cohort study
| Autor: | Sabine Visser, Robin Cornelissen, Bruno H. Stricker, Huub Belderbos, P. de Bruijn, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Stijn L.W. Koolen |
|---|---|
| Přispěvatelé: | Pediatrics, Pulmonary Medicine, Epidemiology, Pharmacy, Medical Oncology |
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Drug-Related Side Effects and Adverse Reactions Population Pemetrexed Disease-Free Survival Cohort Studies 03 medical and health sciences 0302 clinical medicine SDG 3 - Good Health and Well-being Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Dosing education Prospective cohort study Lung cancer Aged education.field_of_study Dose-Response Relationship Drug business.industry Hazard ratio Area under the curve Middle Aged Prognosis medicine.disease Survival Analysis Confidence interval 030104 developmental biology 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | European Journal of Cancer, 121, 64-73. Elsevier Ltd. |
| ISSN: | 0959-8049 |
| Popis: | Background: We explored whether total exposure to pemetrexed predicts effectiveness and toxicity in advanced non–small-cell lung cancer (NSCLC). Furthermore, we investigated alternative dosing schedules. Methods: In this prospective cohort study, patients with advanced NSCLC receiving first- or second-line pemetrexed(/platinum) were enrolled. Plasma sampling was performed weekly (cyclePK) and within 24 h (24hPK) after pemetrexed administration. With population pharmacokinetic/pharmacodynamic modelling, total exposure to pemetrexed during cycle 1 (area under the curve during chemotherapy cycle 1 [AUC1]) was estimated and related to progression-free survival (PFS)/overall survival (OS). We compared mean AUC1 (mg·h/L) in patients with and without severe chemotherapy-related adverse events (AEs) during total treatment. Second, different dosing schedules were simulated to minimise the estimated variability (coefficient of variation [CV]) of AUC. Results: For 106 of 165 patients, concentrations of pemetrexed were quantified (24hPK, n = 15; cyclePK, n = 106). After adjusting for prognostic factors, sex, disease stage and World Health Organisation performance score, AUC1 did not predict PFS/OS in treatment-naive patients (n = 95) (OS, hazard ratio [HR] = 1.05, 95% confidence interval [CI]: 1.00–1.11; PFS, HR = 1.03, 95% CI: 0.98–1.08). Patients with severe chemotherapy-related AEs (n = 55) had significantly higher AUC1 values than patients without them (n = 51) (226 ± 53 vs 190 ± 31, p < 0.001). Compared with body surface area–based dosing (CV: 22.5%), simulation of estimated glomerular filtration rate (eGFR)–based dosing (CV 18.5%) and fixed dose of 900 mg with 25% dose reduction, if the eGFR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect